Subacute thyroiditis following COVID-19 vaccination: Case presentation
Autori
Tomić, AleksandraZafirović, Sonja
![](/themes/MirageVinar/images/orcid.png)
Gluvić, Zoran
![](/themes/MirageVinar/images/orcid.png)
Samardžić, Vladimir
Mačvanin, Mirjana
![](/themes/MirageVinar/images/orcid.png)
Radunović, Maja
Isenović, Esma R.
![](/themes/MirageVinar/images/orcid.png)
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Background:Subacute thyroiditis (SAT) is an organ-specific disease that various drugs, including COVID-19vaccines, can trigger. COVID-19 infection has been associated with thyroid gland damage and disease SARS-CoV-2direct action, euthyroid sick syndrome, and immune-mediated mechanisms are all potential mechanisms of thyroiddamage. It denotes thyroid gland inflammation, most commonly of viral origin, and belongs to the transitory, self-limiting thyroid gland diseases group, causing complications in approximately 15% of patients in the formof permanent hypothyroidism. Some authors say SAT is the most common thyroid disease associated withCOVID-19.Purpose:The occurrence of SAT many weeks after administering the second COVID-19 vaccine is rare and has limiteddocumentation in academic literature. This study aims to present the occurrence of SAT after administering the COVID-19vaccine. We present the case of a 37-year-old man who developed SAT 23 days after receiving the second dose of Pfize...rBioNTech’s COVID-19 mRNA vaccine.Research design and study sample:Due to neck pain and an elevated body temperature (up to 38.2°C), a 37-year-old male subject presented for examination 23 days after receiving the second Pfizer BioNTech mRNA vaccineagainst SARS-CoV-2 viral infection. The patient deniedever having an autoimmune disease or any other disease.Painful neck palpation and afirm, slightly enlarged thyroid gland with no surrounding lymphadenopathy wereidentified during the exam. The heart rate was 104 beatsper minute. All of the remaining physicalfindings werenormal.Data collection and/or Analysis:Data collected during the disease are integral to the medical record.Results:Hematology and biochemistry analyses at the initial and follow-up visits revealed minor leukocytosis, normocyticanaemia, and thrombocytosis, followed by a mild increase in lactate dehydrogenase and decreased iron levels. The patient’sthyroid function and morphology had recovered entirely from post-vaccine SAT.Conclusions: Results from this study emphasise the need for healthcare professionals to promptly report any case of SATrelated to COVID-19 vaccination. Further investigation is warranted to understand the immunopathogenesis of COVID-19-associated thyroiditis and the impact of COVID-19 immunization on this condition.
Ključne reči:
COVID-19 / Pfizer BioNTech vaccine / subacute thyroiditisIzvor:
Antiviral Therapy, 2023, 28, 5Finansiranje / projekti:
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200017 (Univerzitet u Beogradu, Institut za nuklearne nauke Vinča, Beograd-Vinča) (RS-MESTD-inst-2020-200017)
DOI: 10.1177/13596535231208831
ISSN: 1359-6535
PubMed: 37861754
Scopus: 2-s2.0-85174962543
Kolekcije
Institucija/grupa
VinčaTY - JOUR AU - Tomić, Aleksandra AU - Zafirović, Sonja AU - Gluvić, Zoran AU - Samardžić, Vladimir AU - Mačvanin, Mirjana AU - Radunović, Maja AU - Isenović, Esma R. PY - 2023 UR - https://vinar.vin.bg.ac.rs/handle/123456789/11875 AB - Background:Subacute thyroiditis (SAT) is an organ-specific disease that various drugs, including COVID-19vaccines, can trigger. COVID-19 infection has been associated with thyroid gland damage and disease SARS-CoV-2direct action, euthyroid sick syndrome, and immune-mediated mechanisms are all potential mechanisms of thyroiddamage. It denotes thyroid gland inflammation, most commonly of viral origin, and belongs to the transitory, self-limiting thyroid gland diseases group, causing complications in approximately 15% of patients in the formof permanent hypothyroidism. Some authors say SAT is the most common thyroid disease associated withCOVID-19.Purpose:The occurrence of SAT many weeks after administering the second COVID-19 vaccine is rare and has limiteddocumentation in academic literature. This study aims to present the occurrence of SAT after administering the COVID-19vaccine. We present the case of a 37-year-old man who developed SAT 23 days after receiving the second dose of PfizerBioNTech’s COVID-19 mRNA vaccine.Research design and study sample:Due to neck pain and an elevated body temperature (up to 38.2°C), a 37-year-old male subject presented for examination 23 days after receiving the second Pfizer BioNTech mRNA vaccineagainst SARS-CoV-2 viral infection. The patient deniedever having an autoimmune disease or any other disease.Painful neck palpation and afirm, slightly enlarged thyroid gland with no surrounding lymphadenopathy wereidentified during the exam. The heart rate was 104 beatsper minute. All of the remaining physicalfindings werenormal.Data collection and/or Analysis:Data collected during the disease are integral to the medical record.Results:Hematology and biochemistry analyses at the initial and follow-up visits revealed minor leukocytosis, normocyticanaemia, and thrombocytosis, followed by a mild increase in lactate dehydrogenase and decreased iron levels. The patient’sthyroid function and morphology had recovered entirely from post-vaccine SAT.Conclusions: Results from this study emphasise the need for healthcare professionals to promptly report any case of SATrelated to COVID-19 vaccination. Further investigation is warranted to understand the immunopathogenesis of COVID-19-associated thyroiditis and the impact of COVID-19 immunization on this condition. T2 - Antiviral Therapy T1 - Subacute thyroiditis following COVID-19 vaccination: Case presentation VL - 28 IS - 5 DO - 10.1177/13596535231208831 ER -
@article{ author = "Tomić, Aleksandra and Zafirović, Sonja and Gluvić, Zoran and Samardžić, Vladimir and Mačvanin, Mirjana and Radunović, Maja and Isenović, Esma R.", year = "2023", abstract = "Background:Subacute thyroiditis (SAT) is an organ-specific disease that various drugs, including COVID-19vaccines, can trigger. COVID-19 infection has been associated with thyroid gland damage and disease SARS-CoV-2direct action, euthyroid sick syndrome, and immune-mediated mechanisms are all potential mechanisms of thyroiddamage. It denotes thyroid gland inflammation, most commonly of viral origin, and belongs to the transitory, self-limiting thyroid gland diseases group, causing complications in approximately 15% of patients in the formof permanent hypothyroidism. Some authors say SAT is the most common thyroid disease associated withCOVID-19.Purpose:The occurrence of SAT many weeks after administering the second COVID-19 vaccine is rare and has limiteddocumentation in academic literature. This study aims to present the occurrence of SAT after administering the COVID-19vaccine. We present the case of a 37-year-old man who developed SAT 23 days after receiving the second dose of PfizerBioNTech’s COVID-19 mRNA vaccine.Research design and study sample:Due to neck pain and an elevated body temperature (up to 38.2°C), a 37-year-old male subject presented for examination 23 days after receiving the second Pfizer BioNTech mRNA vaccineagainst SARS-CoV-2 viral infection. The patient deniedever having an autoimmune disease or any other disease.Painful neck palpation and afirm, slightly enlarged thyroid gland with no surrounding lymphadenopathy wereidentified during the exam. The heart rate was 104 beatsper minute. All of the remaining physicalfindings werenormal.Data collection and/or Analysis:Data collected during the disease are integral to the medical record.Results:Hematology and biochemistry analyses at the initial and follow-up visits revealed minor leukocytosis, normocyticanaemia, and thrombocytosis, followed by a mild increase in lactate dehydrogenase and decreased iron levels. The patient’sthyroid function and morphology had recovered entirely from post-vaccine SAT.Conclusions: Results from this study emphasise the need for healthcare professionals to promptly report any case of SATrelated to COVID-19 vaccination. Further investigation is warranted to understand the immunopathogenesis of COVID-19-associated thyroiditis and the impact of COVID-19 immunization on this condition.", journal = "Antiviral Therapy", title = "Subacute thyroiditis following COVID-19 vaccination: Case presentation", volume = "28", number = "5", doi = "10.1177/13596535231208831" }
Tomić, A., Zafirović, S., Gluvić, Z., Samardžić, V., Mačvanin, M., Radunović, M.,& Isenović, E. R.. (2023). Subacute thyroiditis following COVID-19 vaccination: Case presentation. in Antiviral Therapy, 28(5). https://doi.org/10.1177/13596535231208831
Tomić A, Zafirović S, Gluvić Z, Samardžić V, Mačvanin M, Radunović M, Isenović ER. Subacute thyroiditis following COVID-19 vaccination: Case presentation. in Antiviral Therapy. 2023;28(5). doi:10.1177/13596535231208831 .
Tomić, Aleksandra, Zafirović, Sonja, Gluvić, Zoran, Samardžić, Vladimir, Mačvanin, Mirjana, Radunović, Maja, Isenović, Esma R., "Subacute thyroiditis following COVID-19 vaccination: Case presentation" in Antiviral Therapy, 28, no. 5 (2023), https://doi.org/10.1177/13596535231208831 . .